Overexpressing KRAS by another KRAS overexpression vector (G12V) in KRAS wild-type CRC cells leads to oxaliplatin sensitivity and ERCC1 downregulation. Yu-Lin Lin Jau-Yu Liau Shan-Chi Yu Da-Liang Ou Liang-In Lin Li-Hui Tseng Yih-Leong Chang Kun-Huei Yeh Ann-Lii Cheng 10.1371/journal.pone.0050701.g004 https://plos.figshare.com/articles/figure/_Overexpressing_KRAS_by_another_KRAS_overexpression_vector_G12V_in_KRAS_wild_type_CRC_cells_leads_to_oxaliplatin_sensitivity_and_ERCC1_downregulation_/206254 <p>(A) KRAS<sup>G12V</sup>-DDK-myc-COLO320DM cells were more sensitive to oxaliplatin, but have the same sensitivity to irinotecan, 5FU, and doxorubicin than parental COLO320DM cells, as demonstrated by MTT assay. (B) The protein level of ERCC1, but not those of TOPO1 or TS, was downregulated after COLO320DM cells were transfected by the KRAS<sup>G12V</sup> mutant vector. (C) The mRNA level of ERCC1, but not those of TOPO1 or TS, was downregulated after COLO320DM cells were transfected by the KRAS<sup>G12V</sup> mutant vector. **: <i>p</i><0.01. (D) Increased percentage of apoptosis, from 22.5%±0.2% to 39.1%±0.2% of apoptosis (P<0.001), has been demonstrated when KRAS<sup>wt</sup>-DDK-myc-COLO320DM cells, were compared to KRAS<sup>G12V</sup>-DDK-myc-COLO320DM cells, in which, both were treated by the same concentration of oxaliplatin in 5 µM. *: <i>p</i><0.001.</p> 2013-02-19 19:39:02 kras overexpression vector wild-type crc cells leads oxaliplatin ercc1